Logo image of POXEL.PA

POXEL SA (POXEL.PA) Stock Fundamental Analysis

EPA:POXEL - Euronext Paris - Matif - FR0012432516 - Common Stock - Currency: EUR

0.257  -0.01 (-4.81%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to POXEL. POXEL was compared to 72 industry peers in the Biotechnology industry. POXEL may be in some trouble as it scores bad on both profitability and health. POXEL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year POXEL has reported negative net income.
In the past year POXEL has reported a negative cash flow from operations.
POXEL had negative earnings in each of the past 5 years.
POXEL had a negative operating cash flow in each of the past 5 years.
POXEL.PA Yearly Net Income VS EBIT VS OCF VS FCFPOXEL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

POXEL's Return On Assets of -727.56% is on the low side compared to the rest of the industry. POXEL is outperformed by 96.88% of its industry peers.
Industry RankSector Rank
ROA -727.56%
ROE N/A
ROIC N/A
ROA(3y)-287.1%
ROA(5y)-189.16%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
POXEL.PA Yearly ROA, ROE, ROICPOXEL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 0.05%, POXEL is in line with its industry, outperforming 43.75% of the companies in the same industry.
In the last couple of years the Gross Margin of POXEL has declined.
POXEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-92.04%
GM growth 5YN/A
POXEL.PA Yearly Profit, Operating, Gross MarginsPOXEL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

POXEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, POXEL has more shares outstanding
Compared to 5 years ago, POXEL has more shares outstanding
The debt/assets ratio for POXEL is higher compared to a year ago.
POXEL.PA Yearly Shares OutstandingPOXEL.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
POXEL.PA Yearly Total Debt VS Total AssetsPOXEL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -33.64, we must say that POXEL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -33.64, POXEL is doing worse than 89.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -33.64
ROIC/WACCN/A
WACC7.3%
POXEL.PA Yearly LT Debt VS Equity VS FCFPOXEL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.34 indicates that POXEL may have some problems paying its short term obligations.
POXEL's Current ratio of 0.34 is on the low side compared to the rest of the industry. POXEL is outperformed by 93.75% of its industry peers.
A Quick Ratio of 0.34 indicates that POXEL may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.34, POXEL is doing worse than 93.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34
POXEL.PA Yearly Current Assets VS Current LiabilitesPOXEL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.16% over the past year.
Looking at the last year, POXEL shows a very strong growth in Revenue. The Revenue has grown by 193.92%.
POXEL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.84% yearly.
EPS 1Y (TTM)0.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.34%
Revenue 1Y (TTM)193.92%
Revenue growth 3Y-33.73%
Revenue growth 5Y-49.84%
Sales Q2Q%73.6%

3.2 Future

The Earnings Per Share is expected to decrease by -32.66% on average over the next years. This is quite bad
The Revenue is expected to grow by 187.77% on average over the next years. This is a very strong growth
EPS Next Y-58.3%
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
EPS Next 5YN/A
Revenue Next Year3450%
Revenue Next 2Y169.26%
Revenue Next 3Y187.77%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
POXEL.PA Yearly Revenue VS EstimatesPOXEL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
POXEL.PA Yearly EPS VS EstimatesPOXEL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for POXEL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for POXEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
POXEL.PA Price Earnings VS Forward Price EarningsPOXEL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

POXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. POXEL is cheaper than 85.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.55
POXEL.PA Per share dataPOXEL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A cheap valuation may be justified as POXEL's earnings are expected to decrease with -32.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%

More info and screens

0

5. Dividend

5.1 Amount

POXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POXEL SA

EPA:POXEL (2/5/2025, 9:25:55 AM)

0.257

-0.01 (-4.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)02-12 2025-02-12/amc
Inst Owners7.99%
Inst Owner ChangeN/A
Ins Owners3.17%
Ins Owner ChangeN/A
Market Cap13.80M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.96
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 10.55
EPS(TTM)-1.08
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.04
BVpS-0.91
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -727.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.05%
FCFM N/A
ROA(3y)-287.1%
ROA(5y)-189.16%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-92.04%
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 9.45
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z -33.64
F-Score2
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.34%
EPS Next Y-58.3%
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
EPS Next 5YN/A
Revenue 1Y (TTM)193.92%
Revenue growth 3Y-33.73%
Revenue growth 5Y-49.84%
Sales Q2Q%73.6%
Revenue Next Year3450%
Revenue Next 2Y169.26%
Revenue Next 3Y187.77%
Revenue Next 5YN/A
EBIT growth 1Y44.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year204.08%
EBIT Next 3Y-1.71%
EBIT Next 5YN/A
FCF growth 1Y35.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.92%
OCF growth 3YN/A
OCF growth 5YN/A